Literature DB >> 9814882

Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir.

D M Burger, P W Hugen, F P Kroon, P Groeneveld, K Brinkman, N A Foudraine, H Sprenger, P P Koopmans, Y A Hekster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9814882     DOI： 10.1097/00002030-199815000-00025

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  8 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 3.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

Authors:  Parya Saberi; Dilrini K Ranatunga; Charles P Quesenberry; Michael J Silverberg
Journal:  Pharmacotherapy       Date:  2011-03       Impact factor: 4.705

5.  Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Authors:  Hiba L Tappouni; John C Rublein; Brian J Donovan; Stephanie B Hollowell; Hsiao-Chuan Tien; Sherene S Min; Dickens Theodore; Naser L Rezk; Philip C Smith; Melanie N Tallman; Ralph H Raasch; Angela D M Kashuba
Journal:  Am J Health Syst Pharm       Date:  2008-03-01       Impact factor: 2.637

Review 6.  Drug interactions between HIV protease inhibitors and acid-reducing agents.

Authors:  Ronald W Falcon; Thomas N Kakuda
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.

Authors:  Ophelia Q P Yin; Frank J Giles; Michele Baccarani; Philipp le Coutre; Ovidiu Chiparus; Neil Gallagher; Giuseppe Saglio; Timothy P Hughes; Andreas Hochhaus; Hagop M Kantarjian; Richard A Larson
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

8.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.

Authors:  Wei Li; Su Zeng; Lu-Shan Yu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-05-27       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.